Eton Pharmaceuticals (ETON) Cash from Financing Activities (2019 - 2025)

Eton Pharmaceuticals has disclosed Cash from Financing Activities across 7 years of filings, most recently posting $421000.0 for Q4 2025.

• Cash from Financing Activities for Q4 2025 came in at $421000.0, down 98.75% year-over-year; the trailing twelve-month figure through Dec 2025 was $815000.0 (down 97.5% YoY), and the FY2025 annual result was $815000.0, down 97.5% from the prior year.
• Cash from Financing Activities came in at $421000.0 for Q4 2025 at Eton Pharmaceuticals, up from $394000.0 in the prior quarter.
• In the past five years, Cash from Financing Activities ranged from a high of $33.6 million in Q4 2024 to a low of -$385000.0 in Q1 2022.
• The 5-year median for Cash from Financing Activities is -$7000.0 (2022), against an average of $1.8 million.
• Across the five-year window, Cash from Financing Activities plunged 1154.29% in 2023 and jumped 11519.05% in 2024, its largest moves.
• Eton Pharmaceuticals' Cash from Financing Activities stood at $68000.0 in 2021, then soared by 45.59% to $99000.0 in 2022, then plunged by 396.97% to -$294000.0 in 2023, then surged by 11519.05% to $33.6 million in 2024, then sank by 98.75% to $421000.0 in 2025.
• The last three Cash from Financing Activities figures came in at $421000.0 (Q4 2025), $394000.0 (Q1 2025), and $33.6 million (Q4 2024), per Business Quant data.